InnovAge (INNV) Competitors

InnovAge (NASDAQ:INNV) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Does the media prefer INNV or PGNY?

In the previous week, Progyny had 15 more articles in the media than InnovAge. MarketBeat recorded 16 mentions for Progyny and 1 mentions for InnovAge. Progyny's average media sentiment score of 1.12 beat InnovAge's score of 0.00 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Progyny	11 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, INNV or PGNY?

InnovAge has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in INNV or PGNY?

12.3% of InnovAge shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 1.4% of InnovAge shares are held by insiders. Comparatively, 9.4% of Progyny shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Do analysts prefer INNV or PGNY?

InnovAge currently has a consensus price target of $5.00, suggesting a potential upside of 31.93%. Progyny has a consensus price target of $25.30, suggesting a potential upside of 12.20%. Given InnovAge's higher probable upside, analysts clearly believe InnovAge is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Progyny	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Which has better valuation & earnings, INNV or PGNY?

Progyny has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$763.85M	0.67	-$21.34M	-$0.23	-16.48
Progyny	$1.17B	1.66	$54.34M	$0.59	38.22

Is INNV or PGNY more profitable?

Progyny has a net margin of 4.28% compared to InnovAge's net margin of -3.75%. Progyny's return on equity of 10.69% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-3.75%	-11.91%	-5.85%
Progyny	4.28%	10.69%	7.12%

Summary

Progyny beats InnovAge on 16 of the 17 factors compared between the two stocks.